AllRock Bio Bet $50 Million That Two ROCKs Are Better Than One

AllRock Bio is a biotech company built around a disagreement with fashion. Drug developers exploring the ROCK family of enzymes had good reason to become picky. Blocking ROCK1 could relax blood vessels so effectively that blood pressure dropped too far. The field drifted toward drugs selective for ROCK2. AllRock looked at the same history and chose both.

Its sole clinical program, ROC-101, is a once-daily pill designed to inhibit ROCK1 and ROCK2. The target is pulmonary hypertension, a family of diseases in which narrowed and remodeled vessels force the heart to pump harder through the lungs. Existing medicines can widen vessels, and the newer drug sotatercept addresses another biological pathway. AllRock's pitch is complementary: keep standard care, then add a drug intended to act on vasoconstriction, inflammation, abnormal cell growth and fibrosis together.

That is the science story. The company story is almost disarmingly practical. Find an asset inside a larger pharmaceutical company. Put people who have done the licensing-and-clinical-development dance before around it. Raise enough money to answer the next expensive question. Do not pretend a platform exists when the value sits in one molecule.

01 / The setupThe sequel begins with an old cast

Catherine Pearce founded AllRock in April 2024 and serves as chief executive. Justin Thompson, its co-founder and chief business officer, had worked with her at CinCor Pharma. There, Pearce built the clinical-stage function while Thompson helped license baxdrostat from Roche. AstraZeneca later acquired CinCor for $1.3 billion upfront and as much as $500 million more. That outcome did not make their next molecule good. It did make the operators legible to investors.

AllRock was formed through JucaBio, a hub-and-spoke drug company that creates focused subsidiaries around licensed assets. ROC-101 came from Sanofi, whose 2021 purchase of Kadmon brought the molecule into its portfolio. The license is exclusive; its price and milestone terms remain private. The only clean public cost is the capital AllRock raised to push the program forward: a $50 million Series A co-led by Versant Ventures and Westlake BioPartners in September 2025.

The origin contains the most copyable part of the playbook. Pearce said the team listened to specialists who emphasized the non-redundant jobs of ROCK1 and ROCK2. That changed the search brief. Rather than begin with a favorite molecule and hunt for a story, AllRock began with a clinical argument, selected an asset that matched it and designed a test around the remaining risk.

“We listened to KOLs and clinicians who emphasized the importance of developing a therapy that blocks the non-redundant roles of both ROCK1 and ROCK2.”Catherine Pearce, CEO and co-founder

02 / The mechanismA four-problem pill, if biology cooperates

ROCK is short for rho-associated coiled-coil-containing protein kinase, which explains why marketers stick with the nickname. The two isoforms help govern muscle contraction, cell movement, inflammation and tissue remodeling. In pulmonary arterial hypertension, the small arteries in the lungs constrict and thicken. In pulmonary hypertension associated with interstitial lung disease, that vascular trouble arrives beside scarred lung tissue. Both conditions can overwhelm the right side of the heart.

In laboratory and animal work published in Pharmacological Research, ROC-101 was selective for its intended kinases, reached lung tissue at concentrations more than ten times those in plasma, and reduced fibrosis, inflammation and vascular remodeling in models of pulmonary disease. Those are useful properties for a lung drug. They are also preclinical results. Mice do not negotiate stairs, fatigue or combination therapy the way people with pulmonary hypertension do.

The Phase 1 study moved the argument into healthy volunteers. AllRock reported tolerability, once-daily pharmacokinetics, target engagement and, most notably, no associated hypotension. Plasma exposure reached levels predicted to inhibit both isoforms. That answers the first worry about the class more cleanly than it answers the only question patients care about: will they feel and function better?

03 / What failed firstThe class lost nerve before this company existed

There is no disclosed AllRock disaster to package into a tidy founder fable. The earlier failure was confidence. Because ROCK1 participates in vascular contraction, broad inhibition carried a systemic blood-pressure concern. Developers shifted toward ROCK2-selective programs in autoimmune and fibrotic disease. AllRock's counterargument is that the isoforms do different, necessary work, and that a sufficiently selective, well-behaved molecule can hit both without unacceptable hypotension.

The company's mind was not changed by a viral paper or a heroic all-nighter. It was changed, by its own account, through specialist conversations. Clinicians wanted the full mechanism. Sanofi had an asset with human safety data capable of testing it. The founders' judgment was to revive the broader target, not because the old risk disappeared, but because ROC-101's early profile suggested it could be managed.

04 / The testForty patients carry the thesis

ROCSTAR is a Phase 2a, open-label, single-arm study planning to enroll about 40 adults with either pulmonary arterial hypertension or pulmonary hypertension associated with interstitial lung disease. Everyone receives ROC-101 alongside standard care, beginning at 10 milligrams daily and escalating to 40 milligrams for the remainder of a 24-week main period. Some participants may already be taking sotatercept. The principal measures are safety and change in pulmonary vascular resistance, captured by right-heart catheterization. Walking distance, a cardiac-stress biomarker and functional class provide other signals.

First patients were dosed by April 2026. The public registry lists 19 locations across the United States, Australia, Canada, France, Germany, Italy, Latvia and Spain, with primary completion estimated for March 2027. That broad map for a small study reveals the practical difficulty of rare cardiopulmonary trials: eligible patients are scattered, heavily treated and managed by specialized centers.

The design is efficient but deliberately limited. Without randomization or a control arm, a positive signal can justify a larger trial, not settle the drug's value. Background therapy can blur attribution. Two distinct patient groups may respond differently. Catheter measurements are objective, but the study is exploratory. AllRock is purchasing information, not a victory lap.

05 / The marketNo customers yet - only users the company hopes to earn

AllRock has no approved product, disclosed revenue or commercial customers. Its prospective users are patients whose pulmonary hypertension remains dangerous despite modern combination therapy. Sixteen drugs across four vasodilator classes already treat PAH, and Merck's Winrevair added a different disease-related pathway. For ILD-PH, options are thinner. ROC-101 is being developed as an add-on, which makes medical sense and commercial life complicated: it must demonstrate value on top of regimens that already do something.

Competitors range from marketed drugs such as Winrevair and United Therapeutics' Tyvaso to experimental remodeling approaches from Gossamer Bio, Pulmovant and others. AllRock's distinction is not “first pulmonary-hypertension pill.” It is the combination of once-daily oral dosing, dual ROCK inhibition and a claim to address multiple remodeling processes without the blood-pressure penalty historically associated with the mechanism.

The business model is standard venture-backed biotech. License a molecule, finance clinical development, create evidence, then raise more money, partner, license the program onward or eventually commercialize it. The $50 million round is substantial for a young company and small beside the cost of global registration studies. If ROCSTAR works, success creates another funding problem. That is normal.

06 / The stealWhat another builder can actually copy

1. Start with the clinical disagreement. AllRock's useful insight was not “fibrosis is big.” It was that both ROCK isoforms may matter and a better molecule might make dual inhibition tolerable.
2. Recruit around the missing proof. Its team spans licensing, clinical operations, regulatory work and pulmonary expertise - the functions required to run the next experiment.
3. Borrow assets, keep conviction. Innovation can be choosing and developing an external molecule better, not owning its first lab notebook.
4. Make the financing legible. One asset, two indications, one Phase 2a study and an explicit use for $50 million is easier to evaluate than a foggy platform promise.

The conditions matter. This playbook does not work if the license is weak, the asset lacks defensible rights, the team cannot recruit specialist sites, or Phase 1 safety is mistaken for patient efficacy. It also fails when an open-label signal is too noisy to finance the randomized study that must follow. Experienced founders can reduce execution risk. They cannot negotiate with biology.

AllRock's achievement so far is disciplined sequence: license, de-risk, finance, dose. Its failure mode is equally plain. If pulmonary vascular resistance barely moves, if side effects emerge at effective exposure, or if mixed patient groups produce an unreadable result, the clever organization will not rescue the molecule. By March 2027, the company expects to have the main study's answer. Until then, AllRock is not proof that two ROCKs are better than one. It is a well-constructed way to find out.